The Library
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease
Tools
(2012) Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. American Heart Journal, Volume 164 (Number 6). pp. 902-909. doi:10.1016/j.ahj.2012.09.018 ISSN 0002-8703.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1016/j.ahj.2012.09.018
Abstract
Background: Left atrial enlargement, a sensitive integrator of left ventricular diastolic function, is associated with increased cardiovascular morbidity and mortality. Vitamin D is linked to lower cardiovascular morbidity, possibly modifying cardiac structure and function; however, firm evidence is lacking. We assessed the effect of an activated vitamin D analog on left atrial volume index (LAVi) in a post hoc analysis of the PRIMO trial (clinicaltrials.gov: NCT00497146). Methods and results: One hundred ninety-six patients with chronic kidney disease (estimated glomerular filtration rate 15-60 mL/min per 1.73m 2), mild to moderate left ventricular hypertrophy, and preserved ejection fraction were randomly assigned to 2 μg of oral paricalcitol or matching placebo for 48 weeks. Two-dimensional echocardiography was obtained at baseline and at 24 and 48 weeks after initiation of therapy. Over the study period, there was a significant decrease in LAVi (-2.79 mL/m 2, 95% CI -4.00 to -1.59 mL/m 2) in the paricalcitol group compared with the placebo group (-0.70 mL/m 2 [95% CI -1.93 to 0.53 mL/m 2], P = .002). Paricalcitol also attenuated the rise in levels of brain natriuretic peptide (10.8% in paricalcitol vs 21.3% in placebo, P = .02). For the entire population, the change in brain natriuretic peptide correlated with change in LAVi (r = 0.17, P = .03). Conclusions: Forty-eight weeks of therapy with an active vitamin D analog reduces LAVi and attenuates the rise of BNP. In a population where only few therapies alter cardiovascular related morbidity and mortality, these post hoc results warrant further confirmation. © 2012 Mosby, Inc. All rights reserved.
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||
Journal or Publication Title: | American Heart Journal | ||||
Publisher: | Mosby, Inc. | ||||
ISSN: | 0002-8703 | ||||
Official Date: | December 2012 | ||||
Dates: |
|
||||
Volume: | Volume 164 | ||||
Number: | Number 6 | ||||
Page Range: | pp. 902-909 | ||||
DOI: | 10.1016/j.ahj.2012.09.018 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Access rights to Published version: | Restricted or Subscription Access |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |